Cargando…

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Kornauth, Christoph, Herbaux, Charles, Boidol, Bernd, Guillemette, Chantal, Caron, Patrick, Mayerhöfer, Marius E., Poulain, Stéphanie, Tournilhac, Olivier, Pemovska, Tea, Chong, Stephen J.F., van der Kouwe, Emiel, Kazianka, Lukas, Hopfinger, Georg, Heintel, Daniel, Jäger, Roland, Raderer, Markus, Jäger, Ulrich, Simonitsch-Klupp, Ingrid, Sperr, Wolfgang R., Kubicek, Stefan, Davids, Matthew S., Staber, Philipp B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327744/ https://www.ncbi.nlm.nih.gov/pubmed/33626863 http://dx.doi.org/10.3324/haematol.2020.271304

Ejemplares similares

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
por: Heinemann, Tim, et al.
Publicado: (2022)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
por: Stühlinger, Markus C., et al.
Publicado: (2019)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
por: Siddiqui, Maria Tariq, et al.
Publicado: (2021)

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
por: Snijder, Berend, et al.
Publicado: (2017)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?
por: Schreiber, Johanna, et al.
Publicado: (2022)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
por: Hampel, Paul J., et al.
Publicado: (2021)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

The Bone’s Role in Myeloid Neoplasia
por: Kazianka, Lukas, et al.
Publicado: (2020)

Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study
por: Schiefer, Ana-Iris, et al.
Publicado: (2015)

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
por: Coelho, H., et al.
Publicado: (2017)

Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma
por: Daniel, Adrien, et al.
Publicado: (2022)

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
por: Kornauth, Christoph, et al.
Publicado: (2022)

Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients
por: Bilgilier, Ceren, et al.
Publicado: (2016)

T-cell Prolymphocytic Leukemia, Cerebriform Variant
por: Carvalho, José, et al.
Publicado: (2021)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

T-cell Prolymphocytic Leukemia Presenting as Red Eye
por: Alwadani, Fahad
Publicado: (2011)

Advances in the understanding and management of T-cell prolymphocytic leukemia
por: Laribi, Kamel, et al.
Publicado: (2017)

An illustrative case of B-cell prolymphocytic leukemia
por: Jain, Ankur, et al.
Publicado: (2020)

Bilateral tonsillar infiltration of T‐cell prolymphocytic leukemia
por: Bertaggia, Ilaria, et al.
Publicado: (2019)

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
por: Varadarajan, Indumathy, et al.
Publicado: (2022)

De-Novo B-Cell Prolymphocytic Leukemia
por: Menakuru, Sasmith R., et al.
Publicado: (2023)

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment
por: Gutierrez, Marc, et al.
Publicado: (2023)

Ultra-early response assessment in lymphoma treatment: [(18)F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
por: Mayerhoefer, Marius E., et al.
Publicado: (2018)

18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging
por: Giraudo, Chiara, et al.
Publicado: (2016)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities
por: Pemovska, Tea, et al.
Publicado: (2021)

Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma
por: PORKERT, Stefanie, et al.
Publicado: (2021)

An Association Between Hypoplastic Myelodysplastic Syndrome and T-Prolymphocytic Leukaemia
por: Arathi, C A, et al.
Publicado: (2011)

T-cell Prolymphocytic Leukemia with Cutaneous Involvement as the Presenting Feature
por: Ashturkar, Amrut V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mc90ma0hr9qdsu0eupuhmg822b